What changing your injection day does to retatrutide exposure, and what it does not

Native glucagon-like peptide-1 has a plasma half-life of roughly one and a half to two minutes. Dipeptidyl peptidase-4 cleaves it between the eighth and ninth residues almost as fast as the gut secretes it. Every marketed GLP-1 receptor agonist is, at bottom, an answer to that problem — and the answers differ enough that treating the class as pharmacokinetically uniform is the single most common error in lay coverage of it.

How you get seven days out of a two-minute peptide

Three engineering strategies account for essentially every long-acting agonist on the market. The first is substitution at the DPP-4 cleavage site: replacing the alanine at position 8 with a residue the enzyme cannot process removes the fastest route of degradation. The second is acylation with a fatty-acid chain, which promotes reversible binding to serum albumin; albumin-bound drug is protected from renal filtration and enzymatic attack, and dissociates slowly to provide a circulating depot. The third is fusion to a large carrier — an immunoglobulin Fc fragment, for instance — which raises the hydrodynamic radius above the glomerular filtration threshold.

Semaglutide uses the first two, with a C18 diacid linked through a spacer. Liraglutide uses a shorter C16 chain and achieves roughly thirteen hours rather than seven days, which is a useful demonstration of how much the chain contributes. Dulaglutide takes the fusion route. The strategies are not interchangeable and they produce different distribution and clearance behaviour, not merely different durations.¹

The accumulation arithmetic, worked

For a drug given at a fixed interval, the accumulation ratio at steady state is approximately 1 / (1 − e^−kτ), where τ is the dosing interval and k is the elimination rate constant, itself 0.693 divided by the half-life. For a once-weekly drug with a seven-day half-life, τ and the half-life are equal, e^−kτ is 0.5, and the accumulation ratio is 2. In plain terms: at an unchanged weekly dose, average concentration at steady state is roughly twice what it is after the first injection.

Time to steady state depends only on the half-life, not on the dose or the interval: about 94% of steady state after four half-lives, 97% after five. For a seven-day half-life that is four to five weeks. This is why a fixed four-week escalation step exists at all — it is approximately the time required for the previous dose to stop increasing — and why escalating faster than that means escalating onto a still-rising exposure curve.

These are approximations that assume linear kinetics and complete absorption. Both assumptions are reasonable for this class and neither is exact.

A missed dose, modelled

Because exposure declines with a seven-day half-life, a single missed weekly dose leaves roughly half the accumulated concentration in circulation at the point the next dose would have been due, and roughly a quarter a week after that. That is why product labelling for once-weekly agonists generally permits taking a missed dose within a defined window and otherwise skipping it, and why a single omission rarely produces a dramatic change.

An interruption of four weeks or more is a different situation. By then concentrations have fallen to a small fraction of steady state, tolerability has substantially reset, and resuming at the previous dose means presenting the receptor with an exposure step it has not seen for a month. The clinical convention — resume lower and re-escalate — follows directly from the pharmacokinetics rather than from caution alone.²

Injection timing: what the kinetics permit

At steady state on a seven-day half-life the peak-to-trough variation across the dosing interval is modest — on the order of tens of per cent rather than folds. Moving the injection by twelve hours, or from one day of the week to another, does not meaningfully change total exposure. It does change when the highest concentrations occur relative to a person’s week.

Time to maximum concentration after subcutaneous injection is on the order of one to three days for the long-acting agonists, so an injection on Friday evening produces its concentration peak somewhere in the weekend. Whether that is desirable is a question about a person’s schedule, not about pharmacology. What the pharmacology does say is that consistency of interval matters more than consistency of hour, because the interval is what determines the accumulation ratio.

Delayed gastric emptying is the mechanism, not the complication

Slowed gastric emptying is frequently described as a side effect. It is more accurately described as a mechanism that becomes an adverse effect at sufficient magnitude. Delayed emptying blunts the post-prandial glucose excursion, which is part of the glycaemic benefit, and it produces early satiety, which is part of the weight effect. Beyond a threshold it produces nausea, vomiting, reflux and the sensation of food sitting undigested.

Two properties of the effect matter clinically. It is dose-dependent, and it exhibits partial tachyphylaxis: the magnitude of delay attenuates over weeks of continued exposure at a fixed dose, which is the physiological basis for the observation that tolerability improves if a dose is held rather than escalated. The residual delay at steady state is real and is the reason pre-procedural fasting guidance for this class exists at all.³

Desensitisation, and what it does and does not explain

Receptor internalisation following agonist binding is well established in vitro, and the popular inference is that "the receptors get used to it", explaining plateaus. The inference outruns the evidence in two ways. First, plateaus in the trials occur at around sixty to seventy weeks and coincide closely with the point at which reduced body mass lowers energy requirement enough to re-establish balance, which is a sufficient explanation without invoking receptor changes. Second, weight regain on withdrawal is rapid and near-complete, which is difficult to reconcile with a model in which the receptor has become unresponsive.

The tolerability tachyphylaxis discussed above — the attenuation of nausea and gastric delay over weeks at a fixed dose — is separately well supported. Two different phenomena share a name, and conflating them produces confident conclusions about plateaus that the data does not license.

What has actually changed in the last three years

Three things, on the Journal’s assessment. First, the demonstration that a dual agonist could produce weight reduction approaching bariatric-surgical magnitude moved the field’s expectations, and with them the design of every subsequent programme. Second, the cardiovascular and renal outcome results reframed the class from metabolic-cosmetic to cardiometabolic, which changed reimbursement arguments far more than it changed prescribing.

Third, and least remarked, the pharmacology of oral administration became tractable. That is a manufacturing and access story as much as a scientific one: an oral small molecule has a completely different cost structure, cold-chain requirement and supply profile from an injectable peptide, and if it holds up in phase 3 it will do more to change who can get treated than any of the receptor science described above.

The next instalment in this department takes up the question this one deliberately set aside: not what the receptor does, but what happens when the molecule reaching it is not quite the molecule on the label. That is an analytical question, and it is answered in a different department.